Announced today, AREVA has formed a new company dedicated to the development of powerful new anti-cancer treatments. AREVA Med LLC will work to target aggressive forms of cancer that currently have limited treatment options. If successful in clinical trails, the new treatments would be used in advanced types of nuclear medicine, such as alpha radio-immunotherapy, for the targeting these aggressive types of cancer. AREVA Med will participate in new treatment development with top oncology centers worldwide. AREVA signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute in Jane 2008 to develop treatment using lead-212. AREVA Inc. President, Jacques Besnainou, said “AREVA Med represents the synthesis of decades of experience in nuclear energy and our company’s long-term commitment to sustainable business approaches, including nuclear materials that could prove beneficial in new applications.”
Share TAGS: AREVA Inc., AREVA Med LLC, AREVA North America, Cancer Treatments, Jacques Besnainou, National Cancer Institute, News, Nuclear Medicine
Posted in: News | View Comments
